Taenia solium porcine cysticercosis: viability of cysticerci and persistency of antibodies and cysticercal antigens after treatment with oxfendazole.
The aim of this study was to assess the effect of treating Taenia solium infected pigs with oxfendazole (OFZ) on viability and clearance of cysticerci and the corresponding persistence of specific antibody isotypes (IgG(total), IgG1, IgG2 and IgA) and circulating cysticercal antigen (CCA). Antibody isotypes and CCA responses were measured by antibody-ELISA (Ab-ELISA) and antigen ELISA (Ag-ELISA), respectively. Correlations were made between antibodies, CCA and the total number of cysticerci enumerated at necropsy. Forty pigs with cysticercosis were randomly allocated into two groups: Treatment group (n=20) was treated with OFZ at 30 mg/kg orally while the treatment control group (n=20) was not treated. Five uninfected pigs served as negative controls. Pigs were killed at 1, 4, 8 and 26 weeks post-treatment (wkpt). Overall, the mean total cyst count in treated pigs was 2904+/-5397 (mean+/-S.D.) while in the controls it was 6235+/-6705. Mean cyst viability was 5+/-11% (mean+/-S.D.) and 97+/-4% in treated and control pigs, respectively. Results showed that OFZ killed muscular cysticerci over a period of 4 weeks but failed to kill cerebral cysticerci. Antibodies, CCA responses and clearance of dead cysts from the meat, depended on the cyst intensity of individual pigs at time of treatment since both antibody and CCA correlated with intensity of cysticerci at necropsy (r=0.441, P=0.005; r=0.654, P<0.001), respectively. IgG1 responses were the best indicator of treatment efficacy because they were predominant in both infected treated and control pigs and disappeared early after treatment. Both Ab/Ag-ELISA failed to detect cysts in the brain. Though dead cysticerci took some time (26 wkpt) to clear from the meat, treatment of porcine cysticercosis with OFZ should, in combination with other intervention measures be considered as an important, cost-effective measure in the control of taeniosis/cysticercosis.
Sikasunge
C S
CS
School of Veterinary Medicine, University of Zambia, P.O. Box 32379, Lusaka, Zambia.
Johansen
M V
MV
Willingham
A L
AL
Leifsson
P S
PS
Phiri
I K
IK
D000818:Animals; D000871:Anthelmintics / Q000191:economics / Q000627:therapeutic use*; D000909:Antibodies, Helminth / Q000097:blood*; D000947:Antigens, Helminth / Q000276:immunology*; D001562:Benzimidazoles / Q000191:economics / Q000627:therapeutic use*; D001921:Brain / Q000469:parasitology; D003362:Cost-Benefit Analysis; D003551:Cysticercosis / Q000188:drug therapy / Q000469:parasitology / Q000662:veterinary*; D003552:Cysticercus / Q000187:drug effects / Q000276:immunology / Q000472:pathogenicity; D004197:Disease Reservoirs; D004797:Enzyme-Linked Immunosorbent Assay / Q000662:veterinary; D005260:Female; D016266:Food Parasitology; D006801:Humans; D008297:Male; D008460:Meat / Q000469:parasitology; D018482:Muscle, Skeletal / Q000469:parasitology; D011897:Random Allocation; D013552:Swine; D013553:Swine Diseases / Q000188:drug therapy* / Q000469:parasitology; D041201:Taenia solium / Q000276:immunology* / Q000472:pathogenicity; D013997:Time Factors; D016896:Treatment Outcome
D000871:Anthelmintics; D000909:Antibodies, Helminth; D000947:Antigens, Helminth; D001562:Benzimidazoles; C011030:oxfendazole